Cell-replacement therapy for Huntington's disease is one of very few therapies that has reported positive outcomes in clinical trials. However, for cell transplantation to be made more readily available, logistical, standardization and ethical issues associated with the current methodology need to be resolved. To achieve these goals, it is imperative that an alternative cell source be identified. One of the key requirements of the cells is that they are capable of acquiring an MSN (medium spiny neuron) morphology, express MSN markers such as DARPP-32 (dopamine-and cAMP-regulated phosphoprotein of 32 kDa), and function in vivo in a manner that replicates those that have been lost to the disease. Developmental biology has progressed in recent years to provide a vast array of information with regard to the key signalling events involved in the proliferation, specification and differentiation of striatal-specific neurons. In the present paper, we review the rationale for cell-replacement therapy in Huntington's disease, discuss some potential donor sources and consider the value of developmental markers in the identification of cells with the potential to develop an MSN phenotype.
Introduction
HD (Huntington's disease) is a triplet repeat disorder characterized by an expansion of the CAG polyglutamine repeat unit of the huntingtin protein. It is an autosomal dominant inherited neurodegenerative disease that affects approx. 4-10 in 10 000 in the Caucasian community. The disease usually manifests in the fourth and fifth decades of life and leads to a relentlessly progressive condition with death most commonly occurring within 20-30 years. The HD brain is characterized by loss of the MSNs (medium spiny neurons) of the striatum, enlargement of the ventricles and a corresponding shrinkage of the overlying cortex (Figure 1 ). Unlike other neurodegenerative disorders, such as Parkinson's disease, where several options are available, albeit mainly for the early-to-moderate-stage patient, there is little in the way of disease-modifying treatment available for patients with HD.
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expression of DARPP-32, (dopamine-and cAMP-regulated phosphoprotein of 32 kDa) [4] . They receive the bulk of inputs to the striatum, receiving afferents from the cortex, thalamus and midbrain, as well as being the major output neuron of the striatum, projecting to various regions of the CNS (central nervous system), including the globus pallidus and the substantia nigra. As such, they form complex neuronal loops within the basal ganglia that are important for the control of action, cognition and emotion [5] .
Cell transplantation in HD
Initial clinical trials of cell transplantation have been undertaken using primary fetal striatal donor tissues [6] [7] [8] [9] . This tissue is obtained from elective termination of pregnancy where the donor has consented to give the tissue for further use. There are, however, several variables associated with the use of human fetal tissue in such trials that are as yet unresolved. The preferred gestational age for donor tissue for brain repair in HD is thought to be in the region of 8-12 weeks postconception by analogy with the stage of development found to be optimal in animal studies [10] , although no systematic study has yet been undertaken using human tissue to optimize the time window with which tissue should be used. Animal studies with rat tissue have shown that younger donor tissue results in optimal graft survival and integration [11, 12] .
A second variable to be considered is that of striatal dissection; clinical studies to date have utilized the WGE (whole ganglionic eminence) as the source of tissue even though the MSNs are derived mainly from the LGE (lateral ganglionic eminence). Most MSNs originate within the LGE, which might therefore be considered to offer an improved source for maximizing the numbers of MSNs within the grafts [13] . Conversely, many of the striatal interneurons originate within the MGE, and may be required for the MSNs to restore normal striatal-like processing of information within the grafts. An animal study has shown that, whereas LGE-only grafts ameliorated functional deficits in animal models when compared with MGE-only grafts, there was greater integration of the graft when WGE was used, thus suggesting that the MGE may indeed be important for full integration of these cells in vivo [14] . However, as with the issue of fetal age, these data are based on animal studies and, as yet, no detailed functional analysis has been carried out using human fetal tissues grafted into animal hosts.
A third variable relates to the manner in which the embryonic tissue is prepared for transplantation. Two methods that have been used in ongoing clinical studies are: (i) enzymatic digestion (using trypsin) of the ganglionic eminences to a quasi-single cell suspension; and (ii) breaking the tissue into small (approx. 1 mm 3 ) pieces manually [9, 15] . No obvious differences in the grafts have been identified as yet, but a meaningful comparison will have to await completion of the two studies. One rodent study in which the two techniques were compared directly reported no major differences in the resulting graft sizes; however, differences in graft connectivity (favouring the suspension grafts) and functional recovery in a skilled motor test (favouring the solid grafts) were reported [14] . As with the donor age and the dissection, a similar study using human fetal tissue has yet to be reported.
Whereas the results from preliminary clinical trials to date have been favourable [7, 9, 15] , although not unequivocal [6] , the therapy is not widely available. The reasons for this may be ethical, logistical or related to quality assurance. The ethical controversies that sometimes surround the use of human fetal tissues can, in our opinion, be adequately addressed by appropriate ethical review, consent and donation [16] . Logistical issues arise mainly due to the scarcity of tissue of the correct age and appropriate integrity for accurate and reliable dissection, and the requirement for use of fresh tissue for surgery. Although limited tissue availability remains a significant challenge, a degree of greater flexibility has been provided by the development of hibernation protocols that provide longer availability of the tissue and better scheduling of surgery [17] . The most difficult issue to resolve is to establish appropriate levels of safety and reproducibility, both for the standardization of tissue dissection and preparation, and the quality assurance of sterility when collecting donor tissues from the products of abortion, and these issues have become even more acute with the introduction of heightened regulatory standards in Europe and elsewhere [18] . Taking the logistical, quality and ethical issues together, there is a compelling and growing need to identify alternative cell sources that would provide the standardization and quality assurance to allow for a more widespread availability of this therapy. As well as identifying an alternative donor cell source, more systematic studies using human fetal tissue in rodent models of the disease are required to standardize the therapy across all centres.
Several donor tissue alternatives are now being actively explored. First, there is the potential to take into culture the primary tissue with a view to expanding the number of progenitors with the potential to differentiate into MSNs, thus avoiding the need for multiple fetal donors per patient. Other possibilities include the use of pluripotential or multipotential stem cells such as ES (embryonic stem) cells and, more recently, iPS (induced pluripotent stem) cells. They have the advantage in that large quantities of cells can be readily generated, although they also present major challenges, critically (i) how to ensure differentiation of all cells to avoid the potential danger of tumour formation, and (ii) how to direct their differentiation into MSNs (with or without other striatal interneurons) capable of functional striatal repair.
In the present review, we focus on some of the potential renewable cell sources that are currently attracting attention as possible sources of donor cells for brain repair, and consider their potential for brain repair in HD. We also consider which cellular markers may be valuable for identification of cells with an MSN potential. Such markers are especially important as tools for the development of protocols to 'direct' stem cells towards a MSN phenotype. Persuading cells to differentiate along a specific cellular lineage may require a sequence of signals to recapitulate elements of normal development, and the generation of protocols for HD brain repair is facilitated greatly by the availability of markers of various stages of MSN normal development.
Potential renewable donor cell sources for HD

Fetal neural precursor cells
The ganglionic eminences can be readily identified and dissected from fetal tissue. These cells can be expanded in culture under defined conditions to generate large numbers of FNPs (fetal-derived neural precursor cells). The addition of growth factors such as EGF (epidermal growth factor) and bFGF-2 (basic fibroblast growth factor-2) enhance the proliferation of these cells over time in culture [19, 20] . Differentiation in vitro has shown that these cells retain the ability to differentiate into all cell types of the nervous system: neurons, astrocytes and oligodendrocytes [21] . More specifically, they can differentiate into DARPP-32-positive neurons after a short period of time in culture. However, since this characteristic declines over time [22] , further investigation into the culture conditions used for the expansion of FNPs over time needs to be carried out to optimize the differentiation into region-specific neurons. It may be that the culture environment is not permissive to such differentiation, insofar as it is very different from the in vivo conditions from which the cells have been taken. Several studies have looked at the differentiation potential of these cells in vivo in animal models of HD [22] [23] [24] [25] [26] , as well as other diseases [27] [28] [29] , and have found that region-specific differentiation can be seen from these cells over time [24] . In a study carried out in our laboratory, we compared the potential of 10-dayexpanded FNPs with that of primary striatal tissue, to send out fibre projections to target regions, such as the globus pallidus and substantia nigra, in the lesioned brain and found that the FNPs did in fact have a greater potential for target innervation in vivo [38] . McBride et al. [30] have reported grafts of human cortical tissue that was expanded in culture for 12 weeks and maintained in vivo for 8 weeks. In these grafts, surviving HuNu (human nuclear antigen)-stained cells were observed in most grafts and were seen to be widely distributed throughout the striatum. Migration of the grafted cells was also reported with HuNu-positive cells observed in the globus pallidus, substantia nigra pars reticulate and the entopeduncular nucleus; however, on no occasion were there HuNu-positive cells reported on the contralateral side of the brain [30] . Grafts of human fetal striatal tissue expanded in culture for 10-12 days to the lesioned striatum for 12 weeks have shown that the grafted cells can send out long fibre projections diffusely in the brain and that these cells differentiate into mature striatal neurons based on their expression of striatal markers such as DARPP-32 [23] .
The migration potential of these cells in vivo has also been studied, and it has been found that expanded neural precursor cells have the potential to migrate out from the graft core. Fricker et al. [25] have shown that human fetal progenitor cells, when placed in neurogenic regions of the adult brain, will migrate to the appropriate targets of that region and differentiate into region-specific neurons [25] . In addition, this the same study also reported non-specific migration of the glial cells to the non-neurogenic striatum [25] .
ES cells
ES cells are derived from the inner cell mass of the blastocyst, and allow large populations of cells to be generated from a single source. Thus they have a potential advantage over FNPs in that much larger numbers can be generated from a single source, presenting greater opportunities for characterization and standardization, although there is emerging evidence of heterogeneity between lines and some phenotypic drift over time. However, if standardized growth conditions allow demonstrable cell line stability, ES cells offer a degree of characterization and quality control not available to other more dynamic or transient sources.
Human and animal ES cells can be neurally differentiated using a number of protocols [31, 32] . One that may readily lend itself to the generation of GMP (good manufacturing practice)-grade cells is the use of serum-free medium, which allows the generation of free-floating (neurosphere-like) spheres of proliferative cells of a neural lineage.
There have also been reports of differentiation of these ES-cell-derived precursors into specific neuronal subtypes such as TH (tyrosine hydroxylase)-positive neurons for use in Parkinson's disease [31, 33, 34] . Behavioural studies using these cells have shown that there can be the potential for circuit reconstruction and alleviation of the lesion deficit [35] [36] [37] , although not all protocols result in cells that can be demonstrated to be functional following transplantation, and the optimum protocol may not yet have been identified.
The generation of DARPP-32-positive neurons from ES cells has not yet been reported. Developmental factors such as Bf1 (brain factor 1), SHH (sonic hedgehog) and FGF-8 (fibroblast growth factor 8) involved in the specification of the telencephalon [38] [39] [40] may be used as markers for differentiation of ES cells. There have been reports of forebrain-specific differentiation from mouse ES-cell-derived neural precursors [41, 42] , by inhibition of Wnt signals using Wnt antagonists, generating a population of cells that are Bf1-positive and Gsh-positive (Gsh is a homeobox gene involved in striatal development). We ourselves have seen DARPP-32-positive cells albeit very few in grafts of human ES-cellderived neural precursor cells derived using similar parameters to that described for the mouse ES cells (A. Battersby, A.E. Rosser and N.D. Allen, unpublished work). With increased understanding of the developmental pathways involved in the formation of DARPP-32-positive neurons, more factors are been identified which may be exogenously added to the culture to enhance the differentiation of these cells.
One of the major risks associated with ES cells is the possibility of tumour formation. Several reports have highlighted the ease with which these cells can form teratomas, and, even after careful differentiation, teratomas have been identified in animals following transplantation [35, 43, 44] . A variety of strategies are under investigation into ways of eliminating remaining undifferentiated (and hence potentially proliferative) ES cells from a population before transplantation, but no reliable method has yet been identified that is compatible with clinical application.
iPS cells
The latest exciting development in finding other possible alternative cell source for transplantation in neurodegenerative diseases is the iPS cell. Although the methodology is still in its infancy, these cells may overcome some important potential obstacles associated with both ES cells and FNPs in that they are less ethically compromised and can potentially be derived specifically for each potential recipient, thus circumventing all major immunological barriers [45, 46] . iPS cells are generated from adult somatic cells by de-differentiation using a cocktail of transcription factors including Oct4 (octamer-binding protein 4), Sox2 (sex-determining region Y box 2), Nanog, Lin28, hTERT (human telomerase reverse transcriptase), SV40L-T (simian virus 40 large T-antigen), KlF4 (kinesin family member 4) and Myc in various combinations [47] [48] [49] [50] [51] . It seems that these cells have very similar properties to ES cells, although this is a very new field and so it is not clear yet whether they will be responsive to cues identified from ES cells for directed differentiation, and whether there will be any, as yet unidentified, additional disadvantages.
Markers of striatal development
For cell-replacement therapy to be viable, it is imperative that the donor tissue is able to generate the precise cell type lost to the disease process, i.e. MSNs for HD. It has been shown that MSNs are derived from Dlx1/2 (distal-less homeobox 1/2)-positive progenitors in the germinal zone of the LGE [52] , from where they migrate into two compartments known as the patch and matrix compartments of the striatum [53] , the latter first followed then by the matrix [54] [55] [56] . TrkB (tropomyosin receptor kinase B) receptor signalling is an important factor in the development of the patch matrix organization of the striatum via its ligand BDNF (brain-derived neutrophic factor) [57] . Other transcription factors also play a role in the control of this process; Mash-1 (mammalian achate schute homologue 1) expressed in the developing striatum influences the cell number as there is a decrease in the amount of defined neuronal populations within the basal ganglia of Mash-1-null mutant mice because of a loss in the number of neuronal progenitors [58, 59] , and migration of matrix neurons within the subventricular zone is inhibited in Dlx1/2 mutant mice [60] .
The function of Gsh2 has been reported to be essential for maintaining the molecular identity of early striatal progenitors [61] . In animals with mutation of the Gsh2 gene, ventral telencephalic regulatory genes such as Mash1 and Dlx are lost; there is a reduction in size of the LGE, but not in the MGE, implicating its importance for dorsal ventral patterning of the developing striatum [61, 62] . Isl-1 (islet-1) has also been reported in the developing striatum; however, the number of positive cells has been shown to decrease from the medial to the lateral striatum, and these cells were double-labelled with choline acetyltransferase, indicating that this population of cells was, in fact, cholinergic. All striatal precursors were found to express Isl-1, but, with maturation, the non-cholinergic cells down-regulated its expression and only cholinergic cells were positive for Isl-1 in the adult striatum [63] .
Other transcription factors are also involved. Ctip2 [COUP-TF (chicken ovalbumin upstream promoter transcription factor)-interacting protein 2] has been found to be exclusively expressed on early post-mitotic MSNs in the striatum. Loss of Ctip2 leads to failure in the ability of these cells to differentiate into mature MSNs, thereby having a dramatic affect on the dysregulation of several striatal genes and affecting the patch and matrix organization of the striatum. As a result of this dysregulation, there is a failure of the MSNs to aggregate into patches, which in turn affects the dopaminergic innervations of the striatum [64] .
FoxP1 (forkhead box P1) and FoxP2 are exclusive to the LGE and are also associated with striatal development. In comparison with the other transcription factors mentioned above, these two genes are also present in the adult brain. FoxP1 is located uniformly in both the patch and matrix compartments, whereas FoxP2 is localized to the patch compartments only [65] . In a recent striatal screen carried out by our laboratory (A.E. Rosser, C.M. Kelly, R. Jeyasingham, N.N. Vinh, V. Pekarik, G.P. Hughes, A. Hodges, L. Jones and M.V. Taylor, unpublished work), we found that FoxP1 was the most up-regulated gene over three time points in development of the mouse striatum. As with Ctip2, we found that FoxP1 and FoxP2 co-localized with DARPP-32-positive cells in the neonatal and adult striatum [64, 66] , and so offers an early developmental marker of DARPP-32-positive neurons.
A third class of gene expression-specific to the LGE is Meis2. Meis2 is regulated by retinoic acid, suggesting that retinoids may also have a role to play in the control of striatal development. Using these transcription factors as developmental cues and understanding their molecular pathways will aid us in directing the differentiation of alternative cell sources and will facilitate the generation of a large population of MSNs for transplantation studies in models of HD.
Conclusions
Developmental biology has progressed to the level that many of the factors associated with the generation and maturation of MSNs have been identified, thus allowing cell biology to progress further with the generation of these mature cells in vitro from various cell types with the aim to have a pool of cells readily available for transplantation studies in patients with HD. However, each alternative source will need to address the same issues relating to reproducibility, stability, safety and quality control, as well as the more complex issues involving directed differentiation into the precise neuronal phenotypes required to replace the function of lost striatal neurons connected within complex neuronal circuits of the host basal ganglia. The analysis of primary fetal striatal grafts has demonstrated that it is not simply sufficient for the cells to express specific mature phenotypes; they also have to integrate within the functional circuitry of the host brain. Further work into understanding the mechanisms by which these factors act will be crucial to the development of this field. Identifying an appropriate source of cells is but the first stage in developing the potential for a viable, reliable and quality-assured cell therapy to be available for functional brain repair in patients. 
